Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC,Extensive Stage × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 395 Melanoma 265 Squamous Cell Carcinoma of Head and Neck 200 Parkinson Disease 4, Autosomal Dominant Lewy Body 163 Neoplasms 156 Breast Neoplasms 144 Triple Negative Breast Neoplasms 139 Neoplasm Metastasis 134 Lung Neoplasms 127 Colorectal Neoplasms 126 Carcinoma, Renal Cell 115 Head and Neck Neoplasms 103 Ovarian Neoplasms 93 Stomach Neoplasms 86 Carcinoma, Transitional Cell 75 Pancreatic Neoplasms 72 Urinary Bladder Neoplasms 70 Carcinoma, Hepatocellular 65 Endometrial Neoplasms 60 Uterine Cervical Neoplasms 57 Esophageal Neoplasms 53 Recurrence 46 Prostatic Neoplasms 44 Glioblastoma 38 Carcinoma 38 Sarcoma 35 Carcinoma, Squamous Cell 34 Lymphoma 32 Fallopian Tube Neoplasms 32 Small Cell Lung Carcinoma 31

Interventions

Etoposide 2 pembrolizumab 1 olaparib 1 niraparib 1 atezolizumab 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05623319 2025-06-24

THOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting

SCLC,Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon ⚡